GPT and type 2 diabetes mellitus: A more recent meta-analysis including 1950 T2DM patients with or without NAFLD showed that SGLT2i therapy for at least 8 weeks significantly reduced the serum concentrations of AST, ALT, and GGT enzymes (Coelho et al., 2021[21]).